地舒单抗治疗骨质疏松的正确用法和效果？

Author: Medicalhalo

Release time: 2025-10-19 11:44:20

Desosumab is effective in treating osteoporosis. On July 15, 2011, Amkin Pharmaceuticals announced that the European Commission approved the marketing of denosumab for the treatment of bone-related diseases caused by solid tumors, including pathological fractures, bone pain caused by radiation therapy, bone marrow compression, etc.

On June 13, 2013, the U.S. FDA approved the expansion of the indications for denosumab to include the treatment of giant cell tumor of bone (GCTB) in adults and some adolescents. This is a rare non-cancerous tumor, and denosumab was therefore granted orphan drug status.

correct

1. Administration method: Desosumab is usually administered by subcutaneous injection, and patients can administer it by themselves after training.

2. Dosage and frequency of administration: The dose and frequency of administration of denosumab will be determined according to the patient's specific conditions, such as the type of disease, severity of the disease, and the patient's weight. In general, the recommended dose of denosumab is 120 mg injected subcutaneously into the upper arm, upper thigh, or abdomen once every four weeks.

3. Duration of treatment course: The duration of treatment course of denosumab will also be determined according to the specific situation of the patient. Typically, treatment lasts from several months to several years, depending on the patient's disease response and tolerability.

4. Regular monitoring: During the period of using denosumab, doctors will conduct regular examinations and monitoring to evaluate the efficacy and side effects of the drug. This may include blood tests, tumor marker testing, and imaging tests.

Desosumab increases bone density and bone mass

Desosumab is a human monoclonal antibody directed against the key bone resorption mediator RANKL and is approved for various indications, including the treatment of postmenopausal (PM) women with osteoporosis who are at increased/high risk of fracture or who have failed/intolerant to other osteoporosis treatments (the indications in this review).

Desosumab has shown benefit in several Phase 3 or 4 studies in women with PM who have osteoporosis or low bone mineral density (BMD), including the pivotal 3-year double-blind free trial and its 7-year open-label extension. Compared with placebo, denosumab reduced the risk of vertebral, nonvertebral, and hip fractures and increased BMD at skeletal sites, and these benefits were maintained over 10 years during the extended period of treatment.

The drug was also more effective than bisphosphonates in improving BMD in the 1-year trial, including in women who switched from a bisphosphonate regimen; however, whether these differences translated into differences in anti-fracture efficacy is unknown. Desosumab is generally well tolerated for up to 10 years of treatment, although an increased risk of multiple vertebral fractures has been observed after discontinuation of treatment.

Therefore, denosumab is a key treatment option for women with osteoporotic PM who are at increased/high risk for fracture or failure/intolerance to other osteoporosis treatments, although the potential for multiple vertebral fractures after discontinuation requires consideration of subsequent management options.

Desosumab reduces fracture risk in osteoporosis patients

Desosumab is a receptor activator of nuclear factor kappa-beta ligand inhibitor, which inhibits the bone resorption process to preserve bone mass. Typically recommended for postmenopausal women and men who are at high risk for fractures. With the recent publication of results from the FREEDOM study and its extension, the long-term effectiveness of denosumab in preventing fragility fractures has been suggested.

Most of the evidence comes from exposure-free trials lasting up to 10 years. Desosumab has been reported to prevent vertebral and nonvertebral fractures. It has also been shown to be effective in Japanese women, chronic kidney disease patients and breast cancer patients undergoing anti-tumor treatment. Discontinuation of denosumab is associated with high remodeling, decreased bone density, and increased fracture risk. These side effects can be prevented with bisphosphonate treatment. The safety profile of denosumab was consistent with increasing years of exposure. In summary, denosumab is a safe and effective option for reducing fracture risk in patients with osteoporosis.

Summary

Desosumab has a good effect in treating osteoporosis. It can reduce bone resorption and destruction, thereby increasing bone density and bone strength and improving osteoporosis. Patients with the above drug indications can consult a doctor in advance and undergo treatment under the guidance of the doctor.